Close Menu

NEW YORK (GenomeWeb) – With several new milestones under its belt, including the CLIA certification of its lab and the launch of a kit version of its RNA-based immune profiling technology (recently rebranded as ImmunoPrism), Cofactor Genomics is hoping to provide tools to a well-established community of sequencing labs for investigating and developing cancer biomarkers in their own facilities.

At the same time, the firm has completed validation of the assay, which it believes will help it lead and support the clinical translation of these biomarkers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.